Multiple Sclerosis Portfolio
Multiple Sclerosis
CommercialActive
Key Facts
About Biogen
Biogen stands as a premier biotechnology company focused on developing innovative therapies for complex neurological, immunological, and rare diseases with significant unmet medical needs. With decades of pioneering work in multiple sclerosis and recent expansions into nephrology through the acquisition of Human Immunology Biosciences, the company maintains a diverse pipeline spanning Alzheimer's disease, ALS, lupus, and other challenging conditions. Biogen's commitment to scientific excellence is demonstrated through substantial annual R&D investment of $2 billion and a global team of over 1,300 research professionals driving innovation from discovery to commercialization.
View full company profileTherapeutic Areas
Other Multiple Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Zeposia (ozanimod) | Bristol Myers Squibb | Commercial |
| Copaxone (glatiramer acetate) | Teva Pharmaceutical Industries | Commercial |
| Kesimpta (ofatumumab) | Genmab | Approved |
| Glatiramer Acetate (Generic Copaxone) | Dr. Reddy's Laboratories | Approved |
| Glatiramer Acetate | Cipla | Commercial |
| Interferon β-1a | Bachem | Commercial |
| KYV-101 | Kyverna Therapeutics | Phase 1/2 |
| Azer-cel (PBCAR0191) | Precision BioSciences | Phase 1/2 |
| CYMS101 | FibroBiologics | Pre-clinical / Limited Clinical |
| BTK allosteric inhibitor | Acellera | Pre-clinical |